Dosing & Uses
Dosage Forms & Strengths
tablet
- 325mg
- 500mg
caplet
- 325mg
- 500mg
- 650mg
capsule
- 325mg
- 500mg
caplet, extended-release
- 650mg
tablet, oral-disintegrating
- 80mg
- 160mg
tablet chewable
- 80mg
solution or suspension, oral
- 160mg/5mL
liquid oral
- 160mg/5mL
- 500mg/5mL
syrup oral
- 160mg/5mL
Analgesia & Fever
immediate-release
- Regular strength: 325-650 mg PO/PR q4hr PRN; not to exceed 3250 mg/day; under supervision of healthcare professional, daily doses of up to 4 g/day may be used
- Extra Strength: 1000 mg PO q6-8hr PRN; not to exceed 3000 mg/day; under supervision of healthcare professional, daily doses of up to 4 g/day may be used:
extended-release
- 2 capsules (1300 mg) PO q8hr PRN; not to exceed 3.9 g/day
maximum dose
- Acetaminophen containing products: Not to exceed a cumulative dose of 3.25 g/day of acetaminophen; under supervision of healthcare professional, daily doses of up to 4 g/day may be used
- Tylenol Extra-Strength (ie, 500 mg/tab or cap): Not to exceed 3 g/day (6 tabs or caps); under supervision of healthcare professional, daily doses of up to 4 g/day may be used
Dosing Considerations
When calculating the maximum daily dose, consider all sources of acetaminophen, including OTC, and routes of administration not to exceed the maximum recommended daily dosing
Renal Impairment
GFR≥50 mL/min: No dosage adjustment necessary
GFR 10-50 mL/min: Administer q6hr
GFR<10mL/min: Administer q8hr
Continuous renal replacement therapy: Administer q6hr
Hepatic Impairment
Use extreme caution; avoid use as much as possible; limit therapy to short-term use at doses not to exceed 2 g/day
Dosage Forms & Strengths
tablet
- 325mg
- 500mg
caplet
- 325mg
- 500mg
- 650mg
capsule
- 325mg
- 500mg
caplet, extended-release
- 650mg
tablet, oral-disintegrating
- 80mg
- 160mg
tablet chewable
- 80mg
solution or suspension, oral
- 160mg/5mL
liquid oral
- 160mg/5mL
- 500mg/5mL
syrup oral
- 160mg5mL
Pain & Fever Relief
Weight-based dosing
- Oral solution
- Neonates 28-31 weeks gestation: 10-15 mg/kg/dose PO q12hr prn; may administer an initial load of 20 mg/kg PO; not to exceed 40 mg/kg/day or 48 hr (consecutive) of maximum dose
- Neonates 32-37 weeks gestation: 10-15 mg/kg/dose PO q8hr prn; may administer an initial load of 20 mg/kg PO; not to exceed 60 mg/kg/day or 48 hr (consecutive) of maximum dose
- Neonates 0-9 days: 10-15 mg/kg/dose PO q6-8hr prn; may administer an initial load of 20 mg/kg PO; not to exceed 60 mg/kg/day; or 48 hr (consecutive) of maximum dose
- Neonates 10-29 days: 10-15 mg/kg/dose PO q4-8hr prn; may administer an initial load of 20 mg/kg PO; not to exceed 90 mg/kg/day; or 48 hr (consecutive) of maximum dose
- Infants: 10-15 mg/kg/dose PO q4-6hr prn; not to exceed 15 mg/kg/dose or 75 mg/kg/day
- Children and adolescents <60 kg: 10-15 mg/kg/dose PO q4-6hr prn; not to exceed 15 mg/kg/dose or 1,000 mg/dose, whichever is less or 75 mg/kg/day or 4,000 mg/day, whichever is less
Fixed dosing
- <6 years: Ask a healthcare provider
- 6-12 years: 325-650 mg PO q4-6hr; not to exceed 1.625 g/day for not more than 5 days unless directed by healthcare provider
>12 years
- Regular strength: 325-650 mg q4-6hr; not to exceed 3.25 g/day; under supervision of healthcare professional, doses of up to 4 g/day may be used
- Extra strength: 1000 mg q6hr; not to exceed 3 g/24hr; under supervision of healthcare professional, doses of up to 4 g/day may be used
- Extended release: 1.3 g q8hr; not to exceed 3.9 g/24hr
Dosing Considerations
When calculating the maximum daily dose, consider all sources of acetaminophen, including OTC, and routes of administration not to exceed the maximum recommended daily dosing
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (3)
- lonafarnib
acetaminophen will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.
- pexidartinib
acetaminophen and pexidartinib both increase Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity.
- pretomanid
acetaminophen, pretomanid. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid.
Monitor Closely (26)
- apalutamide
apalutamide will decrease the level or effect of acetaminophen by increasing elimination. Use Caution/Monitor. Apalutamide induces UGT and may decrease systemic exposure of drugs that are UGT substrates.
- atogepant
acetaminophen will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- avapritinib
acetaminophen will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- axitinib
acetaminophen increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- bupivacaine implant
acetaminophen, bupivacaine implant. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia.
- busulfan
acetaminophen increases levels of busulfan by decreasing metabolism. Use Caution/Monitor. Use of acetaminophen prior to (< 72 hours) or concurrently with busulfan may result in decreased clearance of busulfan due to acetaminophen-induced decreases in glutathione levels.
- dapsone topical
acetaminophen increases toxicity of dapsone topical by altering metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia .
- eltrombopag
eltrombopag increases levels of acetaminophen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear.
- exenatide injectable solution
exenatide injectable solution will decrease the level or effect of acetaminophen by unspecified interaction mechanism. Use Caution/Monitor. To avoid potential interaction, give acetaminophen at least 1 hour before or 4 hours after exenatide injection.
- exenatide injectable suspension
exenatide injectable suspension will decrease the level or effect of acetaminophen by unspecified interaction mechanism. Use Caution/Monitor. To avoid potential interaction, give acetaminophen at least 1 hour before or 4 hours after exenatide injection.
- finerenone
acetaminophen will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or moderate CYP3A4 inhibitors. Adjust finererone dosage as needed.
- flibanserin
acetaminophen will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.
- imatinib
imatinib decreases levels of acetaminophen by decreasing hepatic clearance. Modify Therapy/Monitor Closely. In vitro, imatinib was found to inhibit acetaminophen O-glucuronidation (Ki value of 58.5 micro-M) at therapeutic levels; avoid chronic acetaminophen therapy with imatinib; if occasional acetaminophen administered, do not exceed 1300 mg/day.
- isavuconazonium sulfate
acetaminophen will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- isoniazid
isoniazid will increase the level or effect of acetaminophen by affecting hepatic enzyme CYP2E1 metabolism. Use Caution/Monitor.
- ivacaftor
acetaminophen increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .
- lemborexant
acetaminophen will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.
- levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of acetaminophen by unknown mechanism. Use Caution/Monitor.
acetaminophen increases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by decreasing hepatic clearance. Use Caution/Monitor. Coadministration of ascorbic acid and certain combined hormonal contraceptives (CHCs) containing EE may increase plasma EE concentrations, possibly by inhibition of conjugation. - lixisenatide
lixisenatide will decrease the level or effect of acetaminophen by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. GLP1 agonists delay gastric emptying, which may affect absorption of concomitantly administered oral medications. No effects on acetaminophen Cmax and Tmax were observed when acetaminophen was administered 1 hr before lixisenatide. When administered 1 or 4 hr after lixisenatide, acetaminophen Cmax was decreased by 29% and 31% respectively and median Tmax was delayed by 2 and 1.75 hr, respectively.
- lomitapide
acetaminophen increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.
- midazolam intranasal
acetaminophen will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.
- mipomersen
mipomersen, acetaminophen. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.
- tazemetostat
acetaminophen will increase the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- tetracaine
tetracaine, acetaminophen. Other (see comment). Use Caution/Monitor. Comment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered.
- tinidazole
acetaminophen will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- warfarin
acetaminophen increases effects of warfarin by anticoagulation. Use Caution/Monitor.
Minor (51)
- acetazolamide
acetazolamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- albiglutide
albiglutide decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.
- antithrombin alfa
acetaminophen increases effects of antithrombin alfa by unknown mechanism. Minor/Significance Unknown.
- antithrombin III
acetaminophen increases effects of antithrombin III by unknown mechanism. Minor/Significance Unknown.
- argatroban
acetaminophen increases effects of argatroban by unknown mechanism. Minor/Significance Unknown.
- bemiparin
acetaminophen increases effects of bemiparin by unknown mechanism. Minor/Significance Unknown.
- bivalirudin
acetaminophen increases effects of bivalirudin by unknown mechanism. Minor/Significance Unknown.
- carbamazepine
carbamazepine decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- cholestyramine
cholestyramine decreases levels of acetaminophen by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- clonazepam
clonazepam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- colestipol
colestipol decreases levels of acetaminophen by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- dalteparin
acetaminophen increases effects of dalteparin by unknown mechanism. Minor/Significance Unknown.
- diazepam
diazepam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- disulfiram
disulfiram will increase the level or effect of acetaminophen by affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown.
- enoxaparin
acetaminophen increases effects of enoxaparin by unknown mechanism. Minor/Significance Unknown.
- ethanol
ethanol will decrease the level or effect of acetaminophen by affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown.
ethanol increases toxicity of acetaminophen by decreasing metabolism. Minor/Significance Unknown. - ethosuximide
ethosuximide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- felbamate
felbamate decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- fondaparinux
acetaminophen increases effects of fondaparinux by unknown mechanism. Minor/Significance Unknown.
- fosphenytoin
fosphenytoin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- gabapentin
gabapentin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- gabapentin enacarbil
gabapentin enacarbil decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- green tea
green tea increases effects of acetaminophen by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical, due to caffeine content).
- heparin
acetaminophen increases effects of heparin by unknown mechanism. Minor/Significance Unknown.
- isoniazid
isoniazid increases toxicity of acetaminophen by unknown mechanism. Minor/Significance Unknown.
- lacosamide
lacosamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- lamotrigine
lamotrigine decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- levetiracetam
levetiracetam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- liraglutide
liraglutide decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.
- lorazepam
lorazepam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- methsuximide
methsuximide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- metoclopramide
metoclopramide increases levels of acetaminophen by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- metronidazole
metronidazole will increase the level or effect of acetaminophen by affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown.
- oxcarbazepine
oxcarbazepine decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- oxybutynin
oxybutynin decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.
- oxybutynin topical
oxybutynin topical decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.
- oxybutynin transdermal
oxybutynin transdermal decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.
- phenindione
acetaminophen increases effects of phenindione by unknown mechanism. Minor/Significance Unknown.
- phenobarbital
phenobarbital decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- phenytoin
phenytoin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- primidone
primidone decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- protamine
acetaminophen increases effects of protamine by unknown mechanism. Minor/Significance Unknown.
- rifabutin
rifabutin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- rifampin
rifampin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- rufinamide
rufinamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- ruxolitinib
acetaminophen will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- ruxolitinib topical
acetaminophen will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- tiagabine
tiagabine decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- topiramate
topiramate decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- valproic acid
valproic acid decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- zonisamide
zonisamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism increase levels of hepatotoxic metabolites.
Adverse Effects
Frequency Not Defined
Angioedema
Disorientation
Dizziness
Pruritic maculopapular rash
Rash
Hyperammonemia
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Urticaria
Gastrointestinal hemorrhage
Laryngeal edema
Agranulocytosis
Leukopenia
Neutropenia
Pancytopenia
Thrombocytopenia
Thrombocytopenic purpura
Hepatotoxicity
Liver failure
Nephrotoxicity
Pneumonitis
Anaphylactoid
Warnings
Contraindications
Hypersensitivity
Severe active liver disease
Cautions
Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur
Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose
Use caution in patients with hepatic impairment or active liver disease
Risk of hepatotoxicity is higher in patients taking chronic high dose, or use of more than one acetaminophen-containing product
Use caution in patients with severe renal impairment; consider dosage adjustments
Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage
Use with caution in patients with G6PD deficiency
Use caution in patients with chronic malnutrition
Risk for rare, but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash
Limit acetaminophen dose from all sources and routes to <4 g/day in adults
Pregnancy & Lactation
Pregnancy
Drug crosses placenta and can be detected in cord blood, newborn serum, and urine immediately after delivery
Increased risk of teratogenic effects not reported following maternal use of drug during pregnancy
Use of normal doses during pregnancy not associated with increased risk of miscarriage or still birth; however, increase in fetal death or spontaneous abortion may be seen with maternal overdose if treatment delayed
Wheezing and asthma in early childhood associated with frequent maternal use of drug during pregnancy
Lactation
Drug is excreted in milk; in general, breastfeeding is generally acceptable if relative infant dose (RID) is <10%; avoid breastfeeding when RID>25%
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Acts on hypothalamus to produce antipyresis
May work peripherally to block pain impulse generation; may also inhibit prostaglandin synthesis in CNS
Pharmacokinetics
Peak Plasma Time: 10-60 min (PO immediate-release); 60-120 min (PO extended-release); 6 hr (PO 500 mg, conventional tablet); 8 hr (PO 650 mg, extended-release tablet)
Peak Plasma Concentration: 2.1 mcg/mL (PO 500 mg, conventional tablet); 1.8 mcg/mL (PO 650 mg, extended-release tablet)
Onset: 1 hr
Distribution: 1 L/kg
Protein Bound: 10 to 25%
Metabolism: Liver (microsomal enzyme systems); conjugation (glucuronic/sulfuric acid)
Metabolites: N-acetyl-p-benzoquinoneimine, N-acetylimidoquinone, NAPQI; further metabolized via conjugation with glutathione
Half-life elimination: 1.25-3 hr (adolescents); 2-5 hr (children); 4 hr (infants); 7 hr (neonates); 2-3 hr (adults)
Excretion: urine (principally as acetaminophen glucuronide with acetaminophen sulfate/mercaptate)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Arthritis Pain Reliever oral - | 650 mg tablet |  | |
| Pain Relief Adult oral - | 500 mg/15 mL liquid |  | |
| 8HR Muscle Aches-Pain oral - | 650 mg tablet |  | |
| Arthritis Pain Relief (acetaminophen) oral - | 650 mg tablet | | |
| Arthritis Pain Relief (acetaminophen) oral - | 650 mg tablet | | |
| Silapap oral - | 160 mg/5 mL liquid |  | |
| Silapap oral - | 160 mg/5 mL liquid |  | |
| Pain Relief (acetaminophen) oral - | 325 mg tablet |  | |
| Pain Relief (acetaminophen) oral - | 500 mg tablet |  | |
| Pain Relief (acetaminophen) oral - | 650 mg tablet | | |
| Pain Relief (acetaminophen) oral - | 325 mg tablet |  | |
| Pain Relief (acetaminophen) oral - | 160 mg/5 mL liquid |  | |
| Pain Relief (acetaminophen) oral - | 500 mg tablet |  | |
| Pain Relief (acetaminophen) oral - | 650 mg tablet | | |
| Pain Relief (acetaminophen) oral - | 160 mg/5 mL liquid |  | |
| Pain Relief (acetaminophen) oral - | 500 mg tablet |  | |
| Pain Relief (acetaminophen) oral - | 500 mg tablet |  | |
| Infants' Pain Relief oral - | 160 mg/5 mL suspension |  | |
| Infants' Pain Relief oral - | 160 mg/5 mL suspension |  | |
| Tylenol oral - | 325 mg tablet |  | |
| Tylenol oral - | 325 mg tablet |  | |
| Mapap (acetaminophen) oral - | 325 mg tablet |  | |
| Mapap (acetaminophen) oral - | 500 mg capsule |  | |
| Non-Aspirin oral - | 325 mg tablet |  | |
| Non-Aspirin oral - | 325 mg tablet |  | |
| Non-Aspirin oral - | 325 mg tablet |  | |
| Non-Aspirin oral - | 325 mg tablet |  | |
| Non-Aspirin Extra Strength oral - | 500 mg tablet |  | |
| Non-Aspirin Extra Strength oral - | 500 mg tablet | | |
| Non-Aspirin Extra Strength oral - | 500 mg tablet |  | |
| Pain Reliever (acetaminophen) oral - | 325 mg tablet |  | |
| Pain Reliever (acetaminophen) oral - | 325 mg tablet | | |
| Pain Reliever (acetaminophen) oral - | 500 mg tablet | | |
| Pain Reliever (acetaminophen) oral - | 325 mg tablet |  | |
| Pain Relief Extra Strength oral - | 500 mg tablet | | |
| Pain Relief Extra Strength oral - | 500 mg tablet |  | |
| Pain Relief Extra Strength oral - | 500 mg tablet |  | |
| Pain Relief Extra Strength oral - | 500 mg tablet |  | |
| Little Remedies Fever and Pain Reliever oral - | 160 mg/5 mL liquid |  | |
| M-PAP oral - | 160 mg/5 mL liquid |  | |
| Infants' Pain and Fever oral - | 160 mg/5 mL suspension |  | |
| Pain Reliever Extra Strength oral - | 500 mg tablet | | |
| Pain Reliever Extra Strength oral - | 500 mg tablet |  | |
| Pain Reliever Extra Strength oral - | 500 mg tablet | | |
| Pain Reliever Extra Strength oral - | 500 mg tablet |  | |
| Acetaminophen Extra Strength oral - | 500 mg tablet | | |
| Acetaminophen Extra Strength oral - | 500 mg tablet | | |
| Tylenol Arthritis Pain oral - | 650 mg tablet |  | |
| Infant's Tylenol oral - | 160 mg/5 mL suspension |  | |
| Tylenol 8 Hour oral - | 650 mg tablet | | |
| Tylenol Extra Strength oral - | 500 mg tablet |  | |
| Mapap Arthritis Pain oral - | 650 mg tablet |  | |
| Mapap Arthritis Pain oral - | 650 mg tablet |  | |
| Pharbetol oral - | 500 mg tablet | | |
| Pharbetol oral - | 325 mg tablet |  | |
| Children's Tylenol oral - | 160 mg chewable tablet |  | |
| Children's Tylenol oral - | 160 mg chewable tablet |  | |
| acetaminophen rectal - | 120 mg suppos |  | |
| acetaminophen rectal - | 120 mg suppos |  | |
| acetaminophen rectal - | 650 mg suppos |  | |
| acetaminophen rectal - | 650 mg suppos |  | |
| acetaminophen rectal - | 650 mg suppos |  | |
| Tactinal oral - | 325 mg tablet |  | |
| Feverall rectal - | 80 mg suppos |  | |
| Feverall rectal - | 325 mg suppos |  | |
| Feverall rectal - | 650 mg suppos |  | |
| Feverall rectal - | 325 mg suppos |  | |
| Feverall rectal - | 120 mg suppos |  | |
| Feverall rectal - | 80 mg suppos |  | |
| Feverall rectal - | 120 mg suppos |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL liquid |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain and Fever Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Non-Aspirin oral - | 160 mg/5 mL suspension |  | |
| Children's Non-Aspirin oral - | 160 mg/5 mL suspension |  | |
| Children's Non-Aspirin oral - | 160 mg/5 mL suspension |  | |
| Children's Acetaminophen oral - | 160 mg/5 mL suspension |  | |
| Children's Acetaminophen oral - | 32 mg/mL solution |  | |
| Children's Acetaminophen oral - | 160 mg/5 mL (5 mL) suspension |  | |
| Children's Acetaminophen oral - | 160 mg/5 mL suspension |  | |
| Children's Acetaminophen oral - | 160 mg/5 mL suspension |  | |
| Children's Acetaminophen oral - | 160 mg/5 mL suspension |  | |
| Children's Pain Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Pain Relief oral - | 160 mg/5 mL suspension |  | |
| Children's Fever Reducing rectal - | 120 mg suppos |  | |
| 8 Hour Pain Reliever oral - | 650 mg tablet | | |
| 8 Hour Pain Reliever oral - | 650 mg tablet |  | |
| 8 Hour Pain Reliever oral - | 650 mg tablet | | |
| Ofirmev intravenous - | 1,000 mg/100 mL (10 mg/mL) vial |  | |
| acetaminophen intravenous - | 1,000 mg/100 mL (10 mg/mL) vial |  | |
| acetaminophen intravenous - | 1,000 mg/100 mL (10 mg/mL) vial |  | |
| acetaminophen intravenous - | 1,000 mg/100 mL (10 mg/mL) vial |  | |
| Children's Mapap oral - | 80 mg chewable tablet |  | |
| acetaminophen oral - | 325 mg tablet | | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 325 mg tablet |  | |
| acetaminophen oral - | 500 mg tablet |  | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 500 mg tablet |  | |
| acetaminophen oral - | 650 mg tablet | | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 325 mg tablet | | |
| acetaminophen oral - | 325 mg tablet | | |
| acetaminophen oral - | 325 mg tablet |  | |
| acetaminophen oral - | 325 mg tablet |  | |
| acetaminophen oral - | 500 mg tablet |  | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 500 mg tablet |  | |
| acetaminophen oral - | 325 mg tablet | | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 160 mg/5 mL liquid |  | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 500 mg tablet |  | |
| acetaminophen oral - | 500 mg tablet |  | |
| acetaminophen oral - | 500 mg tablet |  | |
| acetaminophen oral - | 500 mg tablet |  | |
| acetaminophen oral - | 325 mg tablet |  | |
| acetaminophen oral - | 160 mg/5 mL liquid |  | |
| acetaminophen oral - | 325 mg tablet | | |
| acetaminophen oral - | 325 mg tablet | | |
| acetaminophen oral - | 325 mg tablet |  | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 650 mg tablet |  | |
| acetaminophen oral - | 650 mg tablet | | |
| acetaminophen oral - | 650 mg tablet |  | |
| acetaminophen oral - | 80 mg tablet | | |
| acetaminophen oral - | 500 mg tablet | | |
| acetaminophen oral - | 325 mg tablet |  | |
| acetaminophen oral - | 325 mg tablet |  | |
| acetaminophen oral - | 160 mg/5 mL (5 mL) solution |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
acetaminophen rectal
ACETAMINOPHEN SUPPOSITORY - RECTAL
(a-SEET-a-MIN-oh-fen)
COMMON BRAND NAME(S): Acephen, Feverall
WARNING: Taking too much acetaminophen may cause serious (possibly fatal) liver disease. Adults should not take more than 4000 milligrams (4 grams) of acetaminophen a day. People with liver problems and children should take less acetaminophen. Ask your doctor or pharmacist how much acetaminophen is safe to take.Do not use with any other drug containing acetaminophen without asking your doctor or pharmacist first. Acetaminophen is in many nonprescription and prescription medications (such as pain/fever drugs or cough-and-cold products). Check the labels on all your medicines to see if they contain acetaminophen, and ask your pharmacist if you are unsure.Get medical help right away if you take too much acetaminophen (overdose), even if you feel well. Overdose symptoms may include nausea, vomiting, loss of appetite, sweating, stomach/abdominal pain, extreme tiredness, yellowing eyes/skin, and dark urine.Daily alcohol use, especially when combined with acetaminophen, may damage your liver. Avoid alcohol.
USES: This drug is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever.
HOW TO USE: See also Warning section.Use this product rectally as directed. Follow all directions on the product package. If you have any questions, ask your doctor or pharmacist.If you are giving acetaminophen to a child, be sure you use a product that is meant for children. Use your child's age (or weight) to find the right dose on the product package.First, unwrap 1 suppository. Lie down on your left side with right knee bent. If giving to a child, the child may lie on the side or flat on the back. Gently push the suppository into the rectum with your finger. After inserting the suppository, if necessary, hold the buttocks together for 30 to 60 seconds to keep the suppository in place. Remain lying down for a few minutes, and avoid having a bowel movement for an hour or longer so the drug will be absorbed. The suppository is for rectal use only.Pain medications work best if they are used as the first signs of pain occur. If you wait until the symptoms have worsened, the medication may not work as well.Do not use more than recommended. Do not use this medication for fever for more than 3 days unless directed by your doctor. For adults, do not use this product for pain for more than 10 days (5 days in children) unless directed by your doctor. If the child has a sore throat (especially with high fever, headache, or nausea/vomiting), consult the doctor promptly.Tell your doctor if your condition persists or worsens or if you develop new symptoms. If you think you may have a serious medical problem, get medical help right away.
SIDE EFFECTS: See also Warning section.This drug usually has no side effects. If you have any unusual effects, contact your doctor or pharmacist promptly.If your doctor has directed you to use this medication, remember that your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: See also Warning section.Before using acetaminophen, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this product, tell your doctor or pharmacist your medical history, especially of: liver disease, regular use/abuse of alcohol.Tell your doctor if you are pregnant before using this medication.Acetaminophen passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: See also Warning section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug are: ketoconazole, levoketoconazole.This medication may interfere with certain laboratory tests, possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.
OVERDOSE: This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: nausea, vomiting, loss of appetite, sweating, stomach/abdominal pain, extreme tiredness, yellowing eyes/skin, dark urine.
NOTES: Acetaminophen does not cause the stomach and intestinal ulcers that NSAIDs such as aspirin, ibuprofen, and naproxen may cause. However, acetaminophen does not reduce swelling (inflammation) like the NSAIDs do. Consult your doctor for more details and to see which medication might be right for you.
MISSED DOSE: If you are using this medication on a regular basis and miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from heat. If the room temperature is above 80 degrees F (27 degrees C), then store the medication in the refrigerator. Do not freeze. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised January 2022. Copyright(c) 2022 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
